How many drugs treat Secondary hyperparathyroidism?

Drug Landscape tracks 3 marketed treatments for Secondary hyperparathyroidism (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/secondary-hyperparathyroidism.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Secondary hyperparathyroidism — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Secondary hyperparathyroidism (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Secondary hyperparathyroidism, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Parsabiv	ETELCALCETIDE	Kai Pharms Inc	Calcium-sensing Receptor Agonist	CaSR	2017-01-01
Upasita	UPACICALCET	SANWA KAGAKU KENKYUSHO Co., Ltd.		Extracellular calcium-sensing receptor
Orkedia	EVOCALCET	Kyowa Hakko Kirin Co., Ltd.		Extracellular calcium-sensing receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Kai Pharms Inc · 1 drug in Secondary hyperparathyroidism
Kyowa Hakko Kirin Co., Ltd. · 1 drug in Secondary hyperparathyroidism
SANWA KAGAKU KENKYUSHO Co., Ltd. · 1 drug in Secondary hyperparathyroidism

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Secondary hyperparathyroidism:

Cite this brief

Drug Landscape (2026). Secondary hyperparathyroidism — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/secondary-hyperparathyroidism. Accessed 2026-06-10.

Secondary hyperparathyroidism full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing